TwinBeech Capital’s Vir Biotechnology VIR Stock Holding History

TwinBeech Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-291,416	Closed	-$1.89M	–	994
2025 Q1	$1.89M	Buy	+291,416	New	+$2.59M	0.03%	400
2024 Q1	–	Sell	-319,872	Closed	-$3.22M	–	872
2023 Q4	$3.22M	Buy	319,872 +220,712	+223%	+$2.02M	0.05%	334
2023 Q3	$929K	Buy	+99,160	New	+$1.41M	0.02%	500
2023 Q2	–	Sell	-108,507	Closed	-$2.52M	–	878
2023 Q1	$2.52M	Buy	+108,507	New	+$2.78M	0.05%	346
2022 Q4	–	Sell	-165,460	Closed	-$3.19M	–	954
2022 Q3	$3.19M	Buy	+165,460	New	+$4.21M	0.08%	263
2022 Q2	–	Sell	-21,802	Closed	-$561K	–	744
2022 Q1	$561K	Buy	+21,802	New	+$647K	0.02%	384
2021 Q4	–	Sell	-55,974	Closed	-$2.44M	–	830
2021 Q3	$2.44M	Buy	+55,974	New	+$2.42M	0.17%	182

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TwinBeech Capital's VIR Position: Q2 2025 in Review

TwinBeech Capital sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 291,416 shares — an estimated $1.89M sold.

TwinBeech Capital first reported a position in VIR in Q3 2021 and held it in 7 quarters. The position peaked at $3.22M in Q4 2023. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

TwinBeech Capital reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
TwinBeech Capital sold 291,416 Vir Biotechnology shares in Q2 2025, an estimated $1.89M.
TwinBeech Capital first reported a position in Vir Biotechnology in Q3 2021 and held it in 7 quarters.
TwinBeech Capital's Vir Biotechnology position peaked at $3.22M in Q4 2023.
213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.